The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. MapLight Therapeutics Inc shares valued at $16,199,997 were purchased by Novo Holdings A/S on Oct 28 ’25. At $17.00 per share, Novo Holdings A/S acquired 952,941 shares. The insider’s holdings grew to 3,686,622 shares worth approximately $47.89 million following the completion of this transaction.
Also, Catalyst4, Inc. purchased 5,441,176 shares, netting a total of over 92,499,992 in proceeds. Following the buying of shares at $17.00 each, the insider now holds 19,697,464 shares.
As published in their initiating research note from Stifel on November 21, 2025, MapLight Therapeutics Inc [MPLT] has been a Buy and the price target has been revised to $28. Analysts at Morgan Stanley started covering the stock with ‘”an Overweight”‘ outlook in a report released in late November. As of November 21, 2025, Leerink Partners has initiated its “an Outperform” rating for MPLT. Earlier on November 21, 2025, Jefferies initiated its rating. Their recommendation was “a Buy” for MPLT stock.
Analyzing MPLT Stock Performance
On last trading session, MapLight Therapeutics Inc [NASDAQ: MPLT] rose 1.41% to $12.99. The stock’s lowest price that day was $12.25, but it reached a high of $13.07 in the same session. During the last five days, there has been a drop of approximately -11.03%.
Support And Resistance Levels for MapLight Therapeutics Inc (MPLT)
According to the 24-hour chart, there is a support level at 12.46, which, if violated, would cause prices to drop to 11.94. In the upper region, resistance lies at 13.29. The next price resistance is at 13.60. RSI (Relative Strength Index) is 30.57 on the 14-day chart, showing neutral technical sentiment.
Which companies own the most shares of MapLight Therapeutics Inc (MPLT)?
In terms of MapLight Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 31 in the next 12 months, up nearly 142.0% from the previous closing price of $12.81. Analysts anticipate MapLight Therapeutics Inc stock to reach 34 by 2025, with the lowest price target being 28.
